Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 9:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 4,019 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Healthy Volunteer
Interventions: ABBV-903 Tablet Form 1, ABBV-903 Tablet Form 2; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Asthma
Interventions: VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with mouthpiece, VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with facemask, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask, 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece, 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask; Combination Product
Lead sponsor: Vectura Limited; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 2
States / cities: Tempe, Arizona • Anaheim, California

Conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, CD22 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions: Bosutinib, Inotuzumab Ozogamicin; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Peripheral Pulmonary Nodules
Interventions: BF-P190 4 mm thin bronchoscope, BF-MP190F 3 mm ultrathin bronchoscope, Radial ultrasound probe (UM S20-17S), PeriView FLEX 21G Single Use Aspiration Needle; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Caregivers, Family Relations, Domestic Violence, Elder Abuse
Interventions: KINDER; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Bipolar Disorder
Interventions: Family-Focused Treatment Plus Pharmacotherapy, Enhanced Care Plus Pharmacotherapy; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 13 Years to 17 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 3
States / cities: Boulder, Colorado • Cincinnati, Ohio • Pittsburgh, Pennsylvania

Conditions: Multiple Myeloma, Plasma Cell Leukemia
Interventions: ARRY-520, KSP(Eg5) inhibitor; intravenous, Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous, Dexamethasone, steroid; oral; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 5
States / cities: Atlanta, Georgia • Detroit, Michigan • Philadelphia, Pennsylvania + 2 more

Conditions: Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions: ODM-212, Ipilimumab and nivolumab, Gemcitabine and nab-paclitaxel, sotorasib; Drug
Lead sponsor: Orion Corporation, Orion Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 5
States / cities: Los Angeles, California • Orange, California • Fort Worth, Texas + 2 more

Conditions: Healthy
Interventions: Relacorilant 350mg, Itraconazole, Relacorilant 300mg; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions: NHT102, DryNeb; Drug · Device
Lead sponsor: Nob Hill Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Canton, Ohio

Conditions: Diffuse Large B-Cell Lymphoma, B-cell Non-Hodgkin's Lymphoma
Interventions: Debio 1562, Rituximab; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 9
States / cities: Birmingham, Alabama • Urbana, Illinois • Minneapolis, Minnesota + 6 more

Conditions: Alzheimer Disease, Dementia, Mild Cognitive Impairment, Peer-bonded Caregiver, Caregiver
Interventions: Pre-recorded Music Session, Live Music Session; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 50 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology, Oncology Patients, Tumors, Melanoma
Interventions: AMG 232, Trametinib, Dabrafenib; Drug
Lead sponsor: Kartos Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 5
States / cities: Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 2 more

Conditions: Diabetes, Hypertension, Nutrition Poor
Interventions: Produce delivery, Cooking classes; Other
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 64 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Generalized Epidermolysis Bullosa Simplex
Interventions: AC-203, Vehicle; Drug
Lead sponsor: TWi Biotechnology, Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Rancho Santa Margarita, California • Stanford, California • Aurora, Colorado + 4 more

Conditions: Solid Tumor, Adult, Clinical Stage IV Gastric Cancer AJCC v8, Malignant Solid Neoplasm, Metastatic Colorectal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Primary Malignant Brain Neoplasm, Metastatic Sarcoma, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Resectable Colorectal Carcinoma, Resectable Liver and Intrahepatic Bile Duct Carcinoma, Resectable Pancreatic Carcinoma, Resectable Sarcoma, Stage IV Colorectal Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Malignant Brain Neoplasm, Metastatic Breast Carcinoma, Metastatic Liver Carcinoma, Metastatic Pancreatic Carcinoma, Resectable Brain Neoplasm, Resectable Breast Carcinoma, Resectable Gastric Carcinoma, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions: Diagnostic Microscopy, Fluorescein Sodium Injection; Device · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
Interventions: Placebo, Diazoxide Oral Suspension, 2 mg per kg per dose, Deuterated water (2H2O/D2O), 70%, Insulin Suppression Test (IST); Drug · Diagnostic Test
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers
Interventions: GSBR-1290 (Capsule/Tablet), GSBR-1290, Placebo, Placebo (Capsule/Tablet); Drug
Lead sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Miami, Florida • Baltimore, Maryland

Conditions: Vagus Nerve Stimulation
Interventions: Multi-Electrode Array (MEA) Recording; Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Healthy Volunteer
Interventions: ABBV-CLS-616, Placebo, Itraconazole; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Functional Neurological Disorder
Interventions: CBT Informed physical therapy Intervention; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 99 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: CW 002; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 49 Years
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Mucopolysaccharidosis II
Interventions: No Intervention; Other
Lead sponsor: Denali Therapeutics Inc.; Industry
Eligibility: Up to 30 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Oakland, California • Chapel Hill, North Carolina • Pittsburgh, Pennsylvania

Conditions: Neuroblastoma
Interventions: Thiotepa, Cyclophosphamide, Melphalan, Etoposide, Carboplatin, Autologous Stem Cell Infusion, Granulocyte colony stimulating factor; Drug · Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 30 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

A Study to Assess the Relative Bioavailability of Immediate Release Formulations of ABBV-903 in Healthy Adult Participants

A Comparison of VR647 and Conventionally Nebulized Budesonide in Healthy Volunteers and Adult Asthma Subjects

Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML

Thin and Ultrathin Bronchoscopy With Transbronchial Needle Aspiration and Radial Probe Endobronchial Ultrasound for Peripheral Pulmonary Lesions

Knowledge and Interpersonal Skills to Develop Exemplary Relationships

Effectiveness of Family-Focused Treatment Plus Pharmacotherapy for Bipolar Disorder in Adolescents

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

A 2-part Phase 1/2 Open-label Trial on ODM-212

Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites

Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced, Non-small Cell Lung Cancer

Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL

Neurophysiological Benefits of Live Music for Early Alzheimer's Patients and Their Caregivers

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

The Produce Drop: Using Food as Medicine to Lower A1C Levels and Blood Pressure

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Intravital Microscopy in Human Solid Tumors

Effect of Insulin Lowering on Lipogenesis

A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants

Recording Cutaneous Vagal Nerve Activity With Multi-Electrode Array (MEA) in Patients Undergoing VNS Therapy

A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants

Pilot Study of Cognitive Behavioral Therapy-Informed Physical Therapy Intervention in Functional Neurological Disorders

Phase I Clinical Trial to Evaluate the Safety, Pharmacokinetics and Efficacy of CW002

A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome

Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma